story of the week
Canagliflozin Reduces Cardiovascular Events in Patients With Type 2 Diabetes and Chronic Kidney Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Circulation
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Canagliflozin and Cardiovascular and Renal Outcomes in Type 2 Diabetes and Chronic Kidney Disease in Primary and Secondary Cardiovascular Prevention Groups: Results From the Randomized CREDENCE Trial
Circulation 2019 Jul 11;[EPub Ahead of Print], KW Mahaffey, MJ Jardine, S Bompoint, CP Cannon, B Neal, HJL Heerspink, DM Charytan, R Edwards, R Agarwal, G Bakris, S Bull, G Capuano, D de Zeeuw, T Greene, A Levin, C Pollock, T Sun, DC Wheeler, Y Yavin, H Zhang, B Zinman, N Rosenthal, BM Brenner, V PerkovicFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.